Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy

被引：0
|
作者：
Toshio Takagi
Hironori Fukuda
Tsunenori Kondo
Hiroki Ishihara
Kazuhiko Yoshida
Hirohito Kobayashi
Junpei Iizuka
Masayoshi Okumi
Hideki Ishida
Kazunari Tanabe
机构：
[1] Tokyo Women’s Medical University,Department of Urology
[2] Tokyo Women’s Medical University Medical Center East,Department of Urology
来源：
Targeted Oncology | 2019年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：179 / 186
页数：7
相关论文
共 50 条
  • [1] Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy
    Takagi, Toshio
    Fukuda, Hironori
    Kondo, Tsunenori
    Ishihara, Hiroki
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    [J]. TARGETED ONCOLOGY, 2019, 14 (02) : 179 - 186
  • [2] Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
    Takahara, Kiyoshi
    Ando, Ryosuke
    Kanao, Kent
    Ito, Toshiki
    Miyake, Hideaki
    Sumitomo, Makoto
    Yasui, Takahiro
    Shiroki, Ryoichi
    [J]. ANTICANCER RESEARCH, 2020, 40 (08) : 4395 - 4400
  • [3] Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
    Teishima, Jun
    Murata, Daiki
    Inoue, Shogo
    Hayashi, Tetsutaro
    Mita, Koji
    Hasegawa, Yasuhisa
    Kato, Masao
    Kajiwara, Mitsuru
    Shigeta, Masanobu
    Maruyama, Satoshi
    Moriyama, Hiroyuki
    Fujiwara, Seiji
    Matsubara, Akio
    [J]. CURRENT UROLOGY, 2021, 15 (04) : 187 - 192
  • [4] Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC)
    Guida, A.
    Le Teuff, G.
    Colomba, E.
    Baciarello, G.
    Derosa, L.
    Loriot, Y.
    Fizazi, K.
    Massard, C.
    Escudier, B.
    Albiges, L.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC)
    Guida, Annalisa
    Le Teuff, Gwenael
    Colomba, Emeline
    Baciarello, Giulia
    Derosa, Lisa
    Loriot, Yohann
    Fizazi, Karim
    Massard, Christophe
    Escudier, Bernard
    Albiges, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Different outcomes among patients with intermediate-risk metastastic renal cell carcinoma treated with first-line tyrosine-kinase inhibitors
    Pinto, Alvaro
    Miranda, Jesus
    Pertejo, Ana
    Alvarez-Maestro, Mario
    Gonzalez-Peramato, Pilar
    Aguilera, Alfredo
    Garcia, Eugenia
    Trilla, Lucia
    Gamez, Angelo
    Espinosa, Enrique
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (02): : 532 - 537
  • [7] Different outcomes among patients with intermediate-risk metastastic renal cell carcinoma treated with first-line tyrosine-kinase inhibitors
    Álvaro Pinto
    Jesús Miranda
    Ana Pertejo
    Mario Álvarez-Maestro
    Pilar González-Peramato
    Alfredo Aguilera
    Eugenia García
    Lucía Trilla
    Ángelo Gámez
    Enrique Espinosa
    [J]. Clinical and Translational Oncology, 2024, 26 : 532 - 537
  • [8] First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
    Serzan, Michael T.
    Xu, Wenxin
    Berg, Stephanie A.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 951 - 964
  • [9] Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    Yu-Wei Chen
    Brian I. Rini
    [J]. Current Oncology Reports, 2022, 24 : 695 - 702
  • [10] Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    Chen, Yu-Wei
    Rini, Brian, I
    [J]. CURRENT ONCOLOGY REPORTS, 2022, 24 (06) : 695 - 702
12345